AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Saggar Rajeev sold $6.0M of LQDA

Saggar Rajeev (Chief Medical Officer) sold 79,534 shares of Liquidia Corp (LQDA) at an average of $75.09 ($74.06–$76.84, $5.97M total) across 2 trades over 2026-08-17 to 2026-08-19.

Original reporting
SEC EDGAR · Saggar Rajeev
Published Aug 19, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The insider sale provides fresh data on insider sentiment, which traders may use to adjust short-term positions.

02

Market read

New insider sale information for a small-cap biotech, modest relevance for traders tracking insider activity.

03

What to watch

No accompanying corporate news; the sale may be routine and not indicative of future performance.

Relevance 6/10Novelty 6/10Timing: filed Aug 19, 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Medical Officer Saggar Rajeev sold 79,534 shares for $5.97M, reducing his stake to 142,265 shares.

Expected impact

Possible modest downside pressure in the near term.

Evidence & confidence

CMO is a senior insider; a $6M sale is material for a small-cap biotech, but not large enough to trigger a major move.

Market effects

Sector

May raise concerns for biotech sector investors monitoring insider activity.

Regional

Limited to U.S. biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be unrelated to confidence, perhaps for personal financial planning.

Key entities

  • Company
    Liquidia Corp

    Biopharmaceutical company developing drug delivery platforms.

  • Individual
    Saggar Rajeev

    Chief Medical Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com